Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.0K
Overview
64.0K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

343
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
343
Humoral Immune Responses01:36

Humoral Immune Responses

65.6K
Overview
65.6K
What is the Immune System?01:38

What is the Immune System?

98.2K
Overview
98.2K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunopeptidomics of blood coagulation factor IX: a core peptide derived from the protease domain is promiscuously presented on HLA-DR.

Research and practice in thrombosis and haemostasis·2026
Same author

Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.

Blood advances·2026
Same author

Cross-Reactivity of Antiphospholipid Antibodies with Gut Commensal Proteins in Antiphospholipid Syndrome.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Closing in on ADAMTS13 conformation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Establishing reverse chimeric antigen receptor T cells for precise targeting of immunemediated thrombotic thrombocytopenic purpura.

Haematologica·2026
Same author

Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.

Haematologica·2026

Related Experiment Video

Updated: Apr 24, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

15.5K

Acquired TTP: ADAMTS13 meets the immune system.

Fabian C Verbij1, Rob Fijnheer2, Jan Voorberg1

  • 1Department of Plasma Proteins, Sanquin-AMC Landsteiner Laboratory, Amsterdam, The Netherlands.

Blood Reviews
|September 13, 2014
PubMed
Summary

Acquired thrombotic thrombocytopenic purpura (TTP) involves autoantibodies against ADAMTS13. A specific peptide, FINVAPHAR, presented on HLA-DRB1*11, may trigger autoimmune responses, possibly through pathogen mimicry.

Keywords:
ADAMTS13AntibodiesGlycosylationMolecular mimicryReviewTTPThrombotic thrombocytopenic purpura

More Related Videos

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.1K

Related Experiment Videos

Last Updated: Apr 24, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

15.5K
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.1K

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by autoantibodies against ADAMTS13, inhibiting its von Willebrand Factor (VWF) processing.
  • B cell responses often target the ADAMTS13 spacer domain, preventing VWF A2 domain binding.

Purpose of the Study:

  • To review current understanding of ADAMTS13 immune recognition and processing by antigen-presenting cells (APCs).
  • To propose a model for the initiation of autoimmune reactivity in acquired TTP.

Main Methods:

  • Review of existing literature on ADAMTS13 autoantibodies and immune responses.
  • Analysis of HLA-DRB1*11 as a risk factor for acquired TTP.
  • Examination of MHC class II/peptide complexes from ADAMTS13-pulsed dendritic cells.

Main Results:

  • HLA-DRB1*11 is a significant risk factor for acquired TTP.
  • The peptide FINVAPHAR, derived from the ADAMTS13 CUB2 domain, is preferentially presented on HLA-DRB1*11.
  • A model for autoimmune initiation involving mimicry is proposed.

Conclusions:

  • The FINVAPHAR peptide presented on HLA-DRB1*11 is a key factor in acquired TTP pathogenesis.
  • Pathogen-derived peptide mimicry may initiate autoimmune responses against ADAMTS13, leading to TTP.